Login to Your Account


ANCHOR rancor: FDA won’t budge for Amarin on Vascepa decision

By Randy Osborne
Staff Writer

Tuesday, January 21, 2014
“Disappointed but not surprised” by the FDA’s refusal to go back on its surprise withdrawal of the special protocol assessment (SPA) deal for the trial known as ANCHOR, Amarin Corp. plc is moving to the next step in seeking a broader label on the triglyceride-lowering therapy Vascepa (icosapent ethyl), said CEO John Thero.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription